4559:TYO
Zeria Pharmaceutical Co Ltd
2 094,00 JPY
arrow_upward
+0,82%(+17,00) 1 D
19. nov., 13:53:29 GMT+9 · JPY
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4559 …
Åpne
2 070 JPY
Høy
2 105 JPY
Lav
2 062 JPY
Markedsverdi
104,95 mrd.
Snittvolum
133,72k
Volum
58,10k
Utbytte
2,39 %
Kvartalsvis utbytte
13 JPY
Første dato etter utbytte
30. mars 2027
P/E-forhold
8,65
52 u høy
2 434 JPY
52 u lav
1 895 JPY
EPS
242 JPY
Utestående aksjer
50,11 mill.
Antall ansatte
2k
Åpne
2 070 JPY
Høy
2 105 JPY
Lav
2 062 JPY
Markedsverdi
104,95 mrd.
Snittvolum
133,72k
Volum
58,10k
Utbytte
2,39 %
Kvartalsvis utbytte
13 JPY
Første dato etter utbytte
30. mars 2027
P/E-forhold
8,65
52 u høy
2 434 JPY
52 u lav
1 895 JPY
EPS
242 JPY
Utestående aksjer
50,11 mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
The Motley Fool
·
for 1 time siden
The S&P 500 Just Ended a Run of 155 Trading Days Above Its 200-Day Average. Here's What Followed 34 Similar Runs Since 1950.
Barron's
·
for 5 timer siden
Generac Jolted After Nvidia Earnings. Why It’s a Top S&P 500 Stock Today.
Hedgeye
·
for 15 timer siden
Why Negative Gamma Has Taken the Brakes Off the S&P 500
US News Money
·
for 7 timer siden
10 Best S&P 500 Stocks to Buy | Investing
Profil
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Om Zeria Pharmaceutical Co Ltd
Administrerende direktørSachiaki Ibe
Ansatte1,75k
Grunnlagt22. des. 1955
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedzeria.co.jp